Argenx (ARGX) appears confident of a rebound in Q2 with robust Vyvgart momentum amid high demand and record new patient starts in Q1, RBC Capital Markets said in a Wednesday research report.

Vyvgart does not require serotype confirmation before use, potentially eliminating a rate-limiting step in prescribing the medication, but formulary access could take six months, indicating that revenue growth will take time to accelerate, analysts wrote.

Regarding the pipeline, myositis is on track for Q3 and remains the biggest upcoming potential catalyst for the stock, according to the note.

Argenx isn't actively pursuing merger transactions imminently, given the preference for biology bets at early, R&D stage that adds synergistic value to the company's pipeline, RBC stated.

The brokerage said it reiterated its outperform rating on the stock and price target of $890 per share.

Price: 824.04, Change: +15.61, Percent Change: +1.93